

Donald A. Podoloff, M.D.
Professor & Chairman
Department of Nuclear Medicine, University of Texas
M.D. Anderson Cancer Center
Dept. of Nuclear Medicine - Box 083
1515 Holcombe Blvd.
Houston, TX 77030

Donald A. Podoloff, M.D. was trained as an internist at the Beth Israel Medical Center in New York City. He Served in the Air Force as an internist for eighteen months prior to beginning a residency in diagnostic radiology at the USAF Willford Hall Medical Center in San Antonio, Texas. In 1973, at the conclusion of his residency he became the Chief of the Section of Nuclear Medicine at Willford Hall. Dr. Podoloff entered the private practice of nuclear medicine at the Diagnostic Clinic of Houston and remained there until 1986 at which time he joined the staff at the M.D. Anderson Cancer as Deputy Chairman of the Department of Nuclear Medicine to pursue an academic career. He assumed the Chairmanship of the Department of Nuclear Medicine in 1993. Dr. Podoloff has been the Deputy Division Head for Administration in the Division of Diagnostic Imaging since November 1997. He is also the James E. Anderson Professor of Nuclear Medicine.

In 1997, Dr. Podoloff began serving a two year term as the Chairman of the Executive Committee and the Credentials Committee of the Medical Staff. Other MDACC committees that Dr. Podoloff has served on or is currently serving on include chairman of the Term Clinical Tenure Committee (1994-1997), the Professional Liability Committee and the President's Advisory Board. He is also a member of the Medical Board and the Promotion and Tenure Task Force.

He has published seventy seven peer reviewed articles and is known as an expert nationally and internationally in nuclear oncology. He is an Associate Editor of the *Journal of Clinical Cancer Research*. He reviews for many peer reviewed journals in his field including the *Journal of Nuclear Medicine*, *Radiology*, *American Journal of Roentgenology*, *Cancer*, *The Journal of Computer Assisted Tomography*, *The Journal of Head & Neck Surgery*, *Clinical Cancer Research* and *Breast Diseases: A Year Book Quarterly*.

Dr. Podoloff is a Charter Member of the American College of Nuclear Physicians since 1974 and was the Secretary/Treasurer of the organization from 1995 to 1996. He is the President Elect of the College effective February of 1999 and he will assume the Presidency in February 2000. He is the ACNP liaison to the ACR and a member of TRS, HRS ACR, RSNA, ACNM, ACNP and the AMA.

The Role of Radioisotopes and the Treatment of Solid Tumors

An overview of the treatment of solid tumor with radioisotopes. This will include a discussion of colorectal and breast cancer using I-131 labeled CC49. Review the current status of three (3) non-Hodgkin's B-cell lymphoma protocols. We have previously reported our experience using Ho-166 DOTMP in multiple myeloma. Currently we are studying the combination of TBI, systematically administered Ho-166 DOTMP with and without Melphalan. The results of these protocols and the technique for calculating dosimetry and administering the high activity that is required will be discussed.

The remarkable thing about these treatments is the lack of toxicity (except for marrow suppression). No other serious side effects have been encountered to date. The therapies are thus efficacious and safe and the results thus far have been encouraging both in multiple myeloma and in non-Hodgkin's B-cell lymphoma. The results have been less optimal in breast and colon cancer.

At the conclusion of the presentation, the participant should have an understanding of the need for additional production facilities in order to provide a supply of I-131, Ho-166, and Yt-90 and other reactor produced radioisotopes used in therapy of cancer that can be reliably delivered when needed. They should understand the benefits of therapy with these agents.